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ACUTE HEART FAILURE IS A COM-mon cause of emergency ad-mission to hospital.1-3 Theprincipal symptom, dys-
pnea, is thought to be caused by an in-
crease in pulmonary capillary wedge
pressure (PCWP), often associated with
a decrease in stroke volume and car-
diac index and increase in systemic vas-
cular resistance.1-3 The immediate aims
of treatment are to relieve dyspnea and
to improve and stabilize the patient’s he-
modynamic and clinical state.1-5 Addi-
tional goals are prevention of death and
readmission, both of which occur fre-
quently.1-5
Currently, patients with acute heart
failure are treated with drugs that have
a diuretic, vasodilator, or inotropic ac-
tion (or some combination of these ac-
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Context Plasma concentrations of the vasoconstrictor peptide endothelin-1 are in-
creased in patients with heart failure, and higher concentrations are associated with
worse outcomes. Tezosentan is an intravenous short-acting endothelin receptor an-
tagonist that has favorable hemodynamic actions in heart failure.
Objective To determine if tezosentan improves outcomes in patients with acute heart
failure.
Design, Setting, and Participants The Value of Endothelin Receptor Inhibition
With Tezosentan in Acute Heart Failure Studies, 2 independent, identical, and con-
current randomized, double-blind, placebo-controlled, parallel-group trials con-
ducted from April 2003 through January 2005 at sites in Australia, Europe, Israel, and
North America. Patients admitted within the previous 24 hours with persisting dys-
pnea and a respiratory rate of 24/min or greater were eligible provided they fulfilled 2
of 4 criteria: (1) elevated plasma concentrations of B-type or N-terminal pro–B-type
natriuretic peptide, (2) clinical pulmonary edema, (3) radiologic pulmonary conges-
tion or edema, or (4) left ventricular systolic dysfunction.
Intervention Infusion of tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h
for 24 to 72 hours [n=730]) or placebo (n=718).
MainOutcomeMeasures The coprimary end points were change in dyspnea (mea-
sured at 3, 6, and 24 hours using a visual analog scale from 0-100) over 24 hours (as
area under the curve) in the individual trials and incidence of death or worsening heart
failure at 7 days in both trials combined.
Results Of the 1435 patients who received treatment as assigned, 855 (60%) were
men; mean age was 70 years. Mean left ventricular ejection fraction (measured in 779
patients [54%]) was 29% (SD, 11%). Baseline dyspnea scores were similar in the 2 treat-
ment groups. Tezosentan did not improve dyspnea more than placebo in either trial, with
a mean treatment difference of −12 (95% confidence interval [CI], −105 to 81) mm·h
(P=.80) in the first trial and −25 (95% CI, −119 to 69) mm·h (P=.60) in the second. The
incidence of death or worsening heart failure at 7 days in the combined trials was 26% in
each treatment group (odds ratio, 0.99; 95% confidence interval, 0.82-1.21; P=.95).
Conclusion The endothelin receptor antagonist tezosentan did not improve symp-
toms or clinical outcomes in patients with acute heart failure.
Trial Registration clinicaltrials.gov Identifiers: NCT00525707 (VERITAS-1) and
NCT00524433 (VERITAS-2).
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tions), though the evidence base for any
treatment in acute heart failure is weak.1-5
The endothelins are peptides with a
powerful vasoconstrictor action as well
as other effects that could be harmful in
heart failure.6-8 Higher plasma endothe-
lin concentrations also predict worse
clinical outcomes in patients with heart
failure.6-8 Tezosentan is a short-acting en-
dothelin A-type and B-type receptor an-
tagonist developed for intravenous
use.9-13 It is a potent vasodilator that re-
duces systemic vascular resistance and
PCWP and increases cardiac output in
a dose-dependent manner.9-13
The Value of Endothelin Receptor In-
hibition With Tezosentan in Acute
Heart Failure Studies (VERITAS) were
designed to test the hypothesis that
tezosentan would have a favorable effect
on symptoms and clinical outcomes in
patients with acute heart failure.14
METHODS
The VERITAS program consisted of 2
independent, identical, and concur-
rent s tud ies (VERITAS-1 and
VERITAS-2) conducted from April
2003 through January 2005, the de-
sign of which has been described in de-
tail.14 The study was approved by the
ethics committee/independent review
board of each participating hospital.
The steering committee, a group of ad-
visors, and the sponsordesigned the trials
and also met periodically to assess the
progress of the study, address opera-
tional issues, and, at the end of the study,
interpret the results. The independent
data and safety monitoring board
(DSMB)14 met periodically to review
safety data and, after interim analysis, to
review efficacy data. The DSMB was em-
powered to recommend early termina-
tion of the study program for futility (see
below) or if major concerns arose about
the safety of tezosentan. Analysis of data
for the DSMB was carried out by an in-
dependent statistical group.
Study Design
VERITAS-1 and VERITAS-2 were ran-
domized, double-blind, placebo-
controlled, parallel-group studies
(FIGURE 1). Patients were eligible if they
were 18 years or older and met the in-
clusion and exclusion criteria. The key
inclusion criteria were admission to
hospital with acute heart failure within
the previous 24 hours and persistence
of dyspnea at rest. The patient’s report
of dyspnea had to be supported by a res-
piratory rate of at least 24/min. The in-
vestigator’s clinical diagnosis of heart
failure had to be supported by at least
2 of 4 criteria: (1) elevated concentra-
tion of B-type natriuretic peptide (BNP)
or N-terminal pro-BNP, (2) pulmo-
nary edema on physical examination,
(3) radiologic pulmonary congestion or
edema, or (4) left ventricular systolic
dysfunction (left ventricular ejection
fraction [LVEF]40% or wall motion
index 1.2). If the patient had a pul-
monary artery catheter, the cardiac in-
dex (measured as L/min per m2) had to
be 2.5 and the PCWP 20 mm Hg or
greater.
The patient must also have received
at least 1 dose of an intravenous di-
uretic 24 hours or less and 2 hours or
more prior to initiation of the study
drug (or an infusion of diuretic at a con-
stant rate for2 hours). If other intra-
venous treatments were initiated be-
fore the start of study drug, their dose
had to be stable for 2 hours or more for
vasodilators, sympathomimetics, or cal-
cium sensitizers or for 4 hours for phos-
phodiesterase inhibitors and nesiritide.
The exclusion criteria have been de-
scribed in detail and included cardio-
genic shock within 48 hours, ST-
segment elevation myocardial infarction,
ongoing ischemia or administration of a
thrombolytic agent, hypotension (sys-
tolic blood pressure100 mg Hg in pa-
tients not receiving a vasodilator or120
mm Hg in those receiving a vasodila-
tor), anemia (hemoglobin concentra-
tion10 g/dL, hematocrit30%), or re-
naldysfunction(creatinineconcentration
2.5 mg/dL [to convert to µmol/L, mul-
tiply by 88.4]).14 Information on race/
ethnicity was collected for each patient
by means of an investigator check box.
Study Treatment
Afterobtainingwritteninformedconsent,
patientswererandomized24hoursorless
from admission to receive an infusion of
either placebo or tezosentan, 5 mg/h for
30minutes, followedby1mg/hforatleast
24 (and up to 72) hours. Patients in the
placebo group received an identical vol-
umeofsalineinfusion(104mLforthefirst
24 hours). Patients and study investiga-
tors were blinded to study assignment.
Primary End Points
The primary end point of each indi-
vidual VERITAS study was the change
from baseline in dyspnea over the first
24 hours of treatment, measured at 3,
6, and 24 hours as the area under the
curve. Dyspnea was assessed by each
patient using a visual analog scale (VAS)
consisting of a 10-cm vertical line with
the phrase “I am not breathless at all”
at the bottom of the scale and “I am the
most breathless I have ever been” at the
top. The VAS was scored from 0 to 100,
but the patient was unaware of the nu-
merical value of his or her response.
The primary efficacy end point of the
combined studies was the incidence of
deathorworseningheart failureat7days.
Worsening heart failure could occur dur-
ing the index admission or after dis-
charge. Worsening heart failure occur-
ring during initial hospital admission was
defined either as the development of pul-
monary edema, cardiogenic shock, or
other evidence of worsening heart fail-
ure or as lack of improvement in the pa-
tient’s heart failure with treatment (treat-
ment failure). Both definitions required
at least 1 of the following: (1) initiation
of new intravenous therapy, (2) reinsti-
tution of prior intravenous therapy, (3)
increase in current intravenous therapy
for heart failure, (4) implementation of
mechanical circulatory (eg, intra-aortic
balloon pump) or ventilatory (includ-
ing continuous positive airway pres-
sure) support, or (5) use of ultrafiltra-
tion, hemofiltration, or hemodialysis.
Worsening heart failure occurring after
the index admission was defined either
as an unplanned visit to an emergency
department because of worsening heart
failure (pulmonary edema, cardiogenic
shock, or other evidence of worsening
failure) or as unplanned admission be-
cause of worsening heart failure. Both
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definitions required at least 1 of the fol-
lowing: (1) administration of intrave-
nous treatment for heart failure, includ-
ing diuretic, vasodilator, or inotropic
agents; (2) implementation of mechani-
cal, circulatory, or ventilatory support;
or (3) use of ultrafiltration, hemofiltra-
tion, or hemodialysis.
Main Secondary Objectives
The main secondary objectives were to
determine whether tezosentan re-
duced the incidence of death or major
cardiovascular events at 30 days, im-
proved hemodynamic measures over the
first 24 hours (in the subset of patients
with a pulmonary artery catheter in place
for clinical indications), reduced the
Figure 1. Disposition of Patients in VERITAS-1 and VERITAS-2
735 Patients randomized (53 sites) 713 Patients randomized (57 sites)
60 Sites assigned to VERITAS-1 67 Sites assigned to VERITAS-2
145 Sites prospectively assigned 
to VERITAS-1 or VERITAS-2
3760 Patients screened for eligibility 4926 Patients screened for eligibility
363 Followed up through day 7 356 Followed up through day 7 353 Followed up through day 7 344 Followed up through day 7
368 Randomized to receive tezosentan
367 Received treatment as assigned
341 Received treatment for
≥24 h
1 Did not receive treatment
(excluded)
367 Randomized to receive placebo
361 Received placebo as assigned
341 Received placebo for
≥24 h
6 Did not receive placebo
(excluded)
362 Randomized to receive tezosentan
360 Received treatment as assigned
320 Received treatment for
≥24 h
2 Did not receive treatment
(excluded)
351 Randomized to receive placebo
347 Received placebo as assigned
324 Received placebo for
≥24 h
4 Did not receive placebo
(excluded)
169 Followed up through 6 mo 156 Followed up through 6 mo 143 Followed up through 6 mo 147 Followed up through 6 mo
354 Followed up through day 30 343 Followed up through day 30 343 Followed up through day 30 330 Followed up through day 30
361 Included in primary analysis at 24 h
6 Excluded (did not receive study 
treatment)
367 Included in primary analysis at 24 h
1 Excluded (did not receive study 
treatment)
360 Included in primary analysis at 24 h
2 Excluded (did not receive study 
treatment)
347 Included in primary analysis at 24 h
4 Excluded (did not receive study 
treatment)
727 Randomized to receive tezosentan
included in primary analysis at day 7
3 Excluded (did not receive study 
treatment)
708 Randomized to receive placebo
included in primary analysis at day 7
10 Excluded (did not receive study 
treatment)
4 Died 5 Died 7 Died 3 Died
9 Died 13 Died 8 Died
2 Lost to follow-up
13 Died
1 Lost to follow-up
33 Died
2 Lost to follow-up
150 Trial discontinued
prior to 6-mo
follow-up
28 Died
12 Lost to follow-up
143 Trial discontinued
prior to 6-mo
follow-up
39 Died
5 Lost to follow-up
143 Trial discontinued
prior to 6-mo
follow-up
43 Died
13 Lost to follow-up
144 Trial discontinued
prior to 6-mo
follow-up
18 Sites excluded (did not screen for
patients with acute heart failure)
3025 Excluded
140 At sites that did not
enroll patients
2885 Did not meet eligibility
criteria
4213 Excluded
826 At sites that did not
enroll patients
3387 Did not meet eligibility
criteria
VERITAS indicates Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies.
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length of initial hospital admission and
days in hospital up to 30 days, and in-
fluenced 6-month mortality.14
Statistical Analyses
The primary outcome in the indi-
vidual studies, area under the curve of
the change of the dyspnea score from
baseline over the first 24 hours of
treatment, was analyzed as a normally
distributed variable (with an expected
standard deviation of 600 mm·h). The
null hypothesis was tested by means of
the t test against an alternative of a
mean difference of at least 150 mm·h
for the active group compared with
placebo.
The primary outcome in the 2 stud-
ies combined, incidence of death or
worsening heart failure, was analyzed
as a binomial variable. The null hy-
Table 1. Clinical Characteristics of Patients in VERITAS-1 and VERITAS-2
Characteristic
No. (%)
VERITAS-1 VERITAS-2
Tezosentan
(n = 367)
Placebo
(n = 361)
Tezosentan
(n = 360)
Placebo
(n = 347)
Age, mean (SD), y 70 (13) 70 (12) 70 (11) 70 (13)
Sex
Men 220 (60) 222 (61) 222 (62) 191 (55)
Women 147 (40) 139 (39) 138 (38) 156 (45)
Race
White 327 (89) 318 (88) 301 (84) 288 (83)
Black 31 (8) 30 (8) 22 (6) 28 (8)
Other 10 (2) 13 (4) 37 (10) 31 (9)
Criteria for inclusion
Pulmonary congestion
Clinical examination 327 (89) 329 (91) 323 (90) 305 (88)
Radiography 297 (81) 302 (84) 297 (83) 289 (83)
Left ventricular systolic dysfunction 167 (46) 158 (44) 182 (51) 170 (49)
Plasma concentration of BNP
or NT pro-BNP 3 ULN
96 (26) 91 (25) 54 (15) 46 (13)
Cause of heart failure
Ischemic 269 (73) 257 (71) 234 (65) 210 (61)
Hypertensive 97 (26) 115 (32) 126 (35) 122 (35)
Idiopathic 44 (12) 42 (12) 48 (13) 64 (18)
Valvular 13 (4) 20 (6) 15 (4) 11 (3)
Other 21 (6) 20 (6) 27 (8) 32 (9)
History of chronic heart failure 281 (77) 282 (78) 250 (69) 232 (67)
Physiological measurements, mean (SD)
Blood pressure, mm Hg
Systolic 131 (22) 130 (23) 132 (23) 132 (23)
Diastolic 72 (13) 72 (15) 72 (14) 72 (14)
Heart rate, beats per min 81 (17) 82 (18) 82 (18) 84 (17)
Respiratory rate, breaths per min 26.2 (3.8) 26.3 (3.6) 26.2 (4.9) 26.3 (4.3)
LVEF, % 20 (10) 30 (12) 28 (10) 30 (12)
No. with LVEF measurement 195 193 195 196
Laboratory assessments, mean (SD)
Serum sodium, mEq/L 139 (4) 139 (4) 139 (7) 139 (4)
BUN, mg/dL 28.3 (18.0) 27.4 (25.1) 27.2 (12.9) 25.1 (12.9)
Creatinine, mg/dL 1.4 (0.46) 1.3 (0.45) 1.3 (0.43) 1.3 (0.42)
Hemoglobin, g/dL 1.3 (0.19) 1.3 (0.20) 1.3 (0.18) 1.3 (0.19)
Medical history
Hypertension 299 (82) 291 (81) 277 (77) 272 (78)
Myocardial infarction 204 (56) 205 (57) 176 (49) 165 (48)
Diabetes mellitus 165 (45) 166 (46) 191 (53) 162 (47)
Renal impairment 142 (39) 131 (36) 128 (36) 120 (35)
Atrial fibrillation 129 (35) 135 (37) 135 (38) 127 (37)
CABG 84 (23) 87 (24) 74 (21) 63 (18)
Angina pectoris 86 (23) 84 (23) 51 (14) 45 (13)
Stroke 63 (17) 49 (14) 64 (18) 60 (17)
(continued)
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pothesis was tested using the Fisher ex-
act test against the alternative of a risk
reduction of 25% when the active group
was compared with placebo (which was
expected to have an event rate of 35%).
The overall type I error of .05 in the
VERITAS program was split, with .0008
attributed to the analysis of the indi-
vidual studies (.04 to each) and .0492
(or .0092 using a more restrictive over-
all type I error of .01) to the combined
studies. The intent was to submit the
VERITAS program for registration with
the US Food and Drug Administration
for marketing approval if the end point
of death or worsening heart failure
reached a significance level of less than
.01 in the analysis of the combined stud-
ies or if the dyspnea end point was sig-
nificant at less than .04 in the analysis
of each individual study (VERITAS-1
and VERITAS-2) or if the end point of
death or worsening heart failure was
significant at an overall  of .05. Based
on the above conditions and a 90%
power for each of the coprimary end
point analyses, the required sample size
was estimated to be 1760 patients (440
in each group of the 2 studies). Analy-
sis was by intention-to-treat.
Interim analyses of the coprimary
end points were planned to be per-
formed after 50% and 75% of patients
had been randomized. The DSMB
could recommend discontinuation of
the study (for futility) if it was evident
at interim analysis that neither of the
objectives of the program could be ful-
filled. Termination would be advised if
the conditional power (calculated
using the method of stochastic curtail-
ing) fell below 10% for both death or
worsening heart failure at 7 days (at
= .05) and dyspnea (at = .04 for
each study).14 These conditions were
fulfilled at the second interim analysis,
and randomization was stopped on
November 6, 2004. Analyses were per-
formed using SAS version 8.1 (SAS
Institute Inc, Cary, North Carolina).
RESULTS
Between April 11, 2003, and January 20,
2005, 1448 patients were randomized
and evaluated at 110 sites in Australia,
Europe, Israel, and North America: 735
patients at 53 sites in VERITAS-1 and
713 at 57 sites in VERITAS-2. Due to
early termination of the trials for futil-
ity, only 82% of the planned number
of patients (1760) was enrolled. Flow
of patients through the trials is sum-
marized in Figure 1.
Baseline Characteristics
The treatment groups were well bal-
anced inall respects.Of the1435patients
who received treatment as assigned, 855
(60%)weremen; themeanageofpatients
was 70 years. Heart failure was present
beforeadmission in1045(73%),and750
(52%) had a prior history of myocardial
Table 1. Clinical Characteristics of Patients in VERITAS-1 and VERITAS-2 (cont)
Characteristic
No. (%)
VERITAS-1 VERITAS-2
Tezosentan
(n = 367)
Placebo
(n = 361)
Tezosentan
n = 360)
Placebo
(n = 347)
Medical treatment (oral)
Aspirin 236 (64) 237 (66) 213 (59) 190 (55)
ACE inhibitor 197 (54) 202 (56) 179 (50) 185 (53)
-Blocker 177 (48) 169 (47) 164 (46) 161 (46)
Lipid-lowering drug 168 (46) 156 (43) 135 (38) 131 (38)
Loop diuretica 121 (33) 111 (31) 93 (26) 94 (27)
Digoxin 76 (21) 74 (21) 87 (24) 78 (23)
Spironolactone 63 (17) 64 (18) 62 (17) 76 (22)
Calcium antagonist 57 (16) 45 (13) 47 (13) 57 (16)
Amiodarone 45 (12) 52 (14) 43 (12) 27 (8)
Angiotensin receptor blocker 39 (11) 37 (10) 36 (10) 34 (10)
Medical treatment (intravenous)
Nitrate 61 (17) 57 (16) 50 (14) 53 (15)
Nitroprusside 0 1 (0.3) 3 (0.8) 3 (0.9)
Dobutamine 8 (2) 6 (2) 5 (1) 7 (2)
Dopamine 7 (2) 8 (2) 9 (3) 5 (1)
Nesiritide 4 (1) 9 (3) 4 (1) 4 (1)
Milrinone 1 (0.3) 0 0 1 (0.3)
Furosemide-equivalent dose of
intravenous diuretic, mean (SD), mgb
112 (93) 113 (113) 108 (111) 98 (81)
Abbreviations: ACE, angiotensin-converting enzyme; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; LVEF, left ventricular ejection
fraction; NT pro-BNP, N-terminal pro-BNP; ULN, upper limit of normal; VERITAS, Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies.
SI conversion factors: To convert serum sodium values to mmol/L, multiply by 1.0; BUN values to mmol/L, by 0.357; creatinine values to µmol/L, by 88.4; hemoglobin values to g/L,
by 10.0.
aPatients taking an oral loop diuretic at time of randomization (43% were receiving an intravenous loop diuretic at that time); per protocol, 99% of patients had received an intra-
venous loop diuretic 24 and 2 hours prior to study drug initiation.
bAdministered within 24 hours prior to initiation of study treatment. Furosemide (20 mg) = bumetanide (1 mg), ethacrynic acid (25 mg), torasemide (10 mg), and piretanide (6 mg).
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infarction; 1139 (79%) had a history of
hypertension, and the mean systolic
blood pressure at baseline was 132
mm Hg (TABLE 1). Left ventricular ejec-
tion fraction was measured in 779
patients (54%); themean(SD)LVEFwas
29% (11%). Investigators performed
invasivehemodynamicmonitoring in84
patients (6%). The mean (95% confi-
dence interval [CI]) cardiac index was
2.06 (1.97 to 2.18); PCWP, 26 (25 to 27)
mm Hg; and systemic vascular resis-
tance, 1777 (1630 to 1926) dyne·s/cm5.
Criteria for Study Enrollment
The majority of the 1435 patients had
qualified for enrollment by having clini-
cal (1284 [90%]) and radiographic
(1185 [83%]) evidence of pulmonary
congestion or edema. Fewer were en-
rolled on the basis of documented left
ventricular systolic dysfunction (677
[47%]) or an elevated concentration of
BNP (262 [18%]) or N-terminal pro-
BNP (32 [2%]).
Treatment at Baseline
As planned, all patients received an in-
travenous direutic. An angiotensin-
converting enzyme inhibitor or angio-
tensin receptor blocker was used at the
time of randomization in 909 (63%), a
-blocker in 671 (47%), and spirono-
lactone in 265 (19%). Very few pa-
tients received other intravenous va-
soactive agents at baseline or during
infusion of study drug: 221 (15%) re-
ceived nitrates at baseline (20% dur-
ing study drug infusion), 26 (1.8%) re-
ceived dobutamine(3.3%), 7 (0.5%)
received nitroprusside (1.1%), 21
(1.5%) received nesiritide (2.9%), 29
(2.0%) received dopamine (4.5%), and
2 (0.1%) received milrinone (0.6%).
Study Drug Administration
Study drug was received as assigned by
727 of 730 (99.6%) patients assigned
to receive tezosentan and 708 of 718
(98.6%) assigned to receive placebo
(Figure 1). The median time from ad-
mission to the start of study drug was
11 hours. At least 24 hours of treat-
ment was received by 661 of 727 (91%)
patients given tezosentan and 665 of
708 (94%) given placebo.
Change in Dyspnea
The mean (95% CI) VAS score for dys-
pnea at baseline was 66.5 (64.2 to 68.8)
in the tezosentan group and 63.7 (61.5
to 65.9) in the placebo group at base-
line in VERITAS-1; the corresponding
scores in VERITAS-2 were 60.3 (57.7 to
62.9) and 59.4 (56.7 to 62.0), respec-
tively, where a higher score indicated
greater dyspnea. The level of dyspnea de-
creased rapidly in both treatment groups
after randomization (FIGURE 2). The
coprimary end point of the area under
the curve of the change in dyspnea from
baseline was similar in each treatment
group in both VERITAS-1 and
VERITAS-2. In VERITAS-1, the mean
(95% CI) change was −562 (−628 to
−497) mm·h in the tezosentan group
and −550 (−617 to −483) in the pla-
cebo group (difference between treat-
ments, −12 [−105 to 81] mm·h;P=.80).
In VERITAS-2, the corresponding
change in the tezosentan group was
−367 (−432 to −302) mm·h and in the
placebo group was −342 (−410 to −274)
(difference between treatments, −25
[−119 to 69] mm·h; P=.60).
There was no difference between
tezosentan and placebo in key un-
planned subgroups (FIGURE 3). The re-
sponse in patients with baseline VAS
scores for dyspnea above and below the
median (65 mm) was similar. Simi-
larly, a preplanned exploratory analy-
sis of the change in rate of respiration
(area under the curve analysis) showed
no difference between tezosentan and
placebo; in VERITAS-1 and VERITAS-2
combined, the mean (95% CI) change
in the tezosentan group was −32 (−50
to −15) breaths/min·h and in the pla-
cebo group was −26 (−43 to −9) (dif-
ference between treatments, −6.4 [−31
to 18]; P=.61).
The mean (95% CI) change in the
area under the curve for dyspnea change
did not differ between treatment groups
in the subset of 84 patients monitored
hemodynamically (treatment differ-
ence, −5 [−328 to 318]; P=.97), and the
Figure 2. Change in Dyspnea in VERITAS-1 and VERITAS-2
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bars indicate 95% confidence intervals.
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treatment difference did not differ sig-
nificantly between patients who were
and were not monitored hemodynami-
cally (P=.89 for interaction).
Death or Worsening Heart Failure
Up to 7 Days
The incidence of the coprimary end point
of death or worsening heart failure up to
7 days from randomization in
VERITAS-1 and VERITAS-2 combined
is shown in TABLE 2. In both treatment
groups, 26% of patients experienced this
composite outcome (odds ratio, 0.99;
95% CI, 0.82 to 1.21; P=.95). The effect
of tezosentancomparedwithplacebowas
similar across a range of unplanned sub-
groups, including those defined by sex,
age, etiology, LVEF, comorbidity, base-
line blood pressure, and renal function
and concomitant treatment.
Secondary and Exploratory
End Points
The secondary end point of the inci-
dence of death or worsening heart fail-
ure up to 30 days was 32% in the
tezosentan group and 33% in the pla-
cebo group (Table 2). The incidence of
the composite outcome of death or a
major cardiovascular event at 7 days
and 30 days is summarized in Table 2.
The mean (SD) number of days spent
in hospital during the index admis-
sion after randomization was 9 (7) in
both treatment groups and from ran-
domization to day 30 was 11 (8) in each
treatment group.
The number of deaths at 6 months
was 104 (14.3%) in the tezosentan
group and 101 (14.3%) in the placebo
group (hazard ratio, 1.01; 95% CI, 0.77
to 1.33).
Changes in Hemodynamic
Measurements
Changes in key hemodynamic mea-
surements at 3, 6, and 24 hours from
start of study drug were secondary end
points and are summarized inTABLE 3.
Greater decreases in PCWP, right atrial
pressure, and pulmonary and sys-
temic vascular resistance and a trend to
a greater increase in cardiac index were
observed in the tezosentan group.
Figure 3. Change in Dyspnea Over 24 Hours in Key Subgroups of VERITAS-1 and VERITAS-2
–300 2000–200 100–100
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Tertile 3 (≥75)
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Respiration rate (breaths per min)
<Median (26)
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164 148 –27 (–160 to 105)Tertile 2 (24-26)
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126 117 40 (–108 to 188)
97 93 –9 (–160 to 143)Tertile 1 (<50)
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Respiration rate (breaths per min)
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Dyspnea VAS (score)
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VERITAS-2
Mean Difference (95% CI)
Mean Difference (95% CI)
360 347 –25 (–119 to 69)All patients
Change in dyspnea shown as placebo-corrected area under the curve. CI indicates confidence interval; VAS, visual
analog scale; VERITAS, Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies.
Error bars indicate 95% confidence intervals.
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By 24 hours, the mean (SD) decrease
in systolic blood pressure was 14.6
(18.3) mm Hg in the tezosentan group
and −8.5 (21.1) mm Hg in the placebo
group, a statistically significant differ-
ence of −6.1 (95% CI, −8.2 to −4.1)
mm Hg (P .0001). The mean (SD)
decrease in diastolic blood pressure was
−9.7 (13.7) mm Hg in the tezosentan
group and −4.4 (14.3) mm Hg in the
placebo group, a statistically signifi-
cant difference of −5.3 (95% CI, −6.7
to −3.8) mm Hg (P .0001).
Safety and Adverse Effects
Of 727 tezosentan-treated and 708 pla-
cebo-treated patients, 103 (14.2%) and
68 (9.6%), respectively, stopped the
study drug because of an adverse effect
(P=.008).Thisdifferencewasmainlydue
to hypotension (leading to discontinu-
ation in 60 [8.3%] in the tezosentan
group and 33 [4.7%] in the placebo-
treated group, P=.003), which was the
most common adverse effect associated
with discontinuation. Overall, hypoten-
sion up to 5 days after study drug initia-
tion was reported as an adverse effect in
165 of tezosentan-treated patients
(22.7%) and 103 placebo-treated pa-
Table 2. Primary (Death or Worsening Heart Failure) and Secondary (Death or Major
Cardiovascular Event) End Points Up to Day 7 and Day 30
No. (%)
Day 7 Day 30
Tezosentan
(n = 727)
Placebo
(n = 708)
Tezosentan
(n = 727)
Placebo
(n = 708)
Death or Worsening Heart Failure
Patients with an eventa 191 (26.3) 187 (26.4) 232 (31.9) 235 (33.2)
Eventsb
Death 11 (1.5) 8 (1.1) 28 (3.9) 34 (4.8)
Cardiogenic shock 3 (0.4) 5 (0.7) 2 (0.3) 4 (0.6)
Pulmonary edema 47 (6.5) 39 (5.5) 61 (8.4) 55 (7.8)
Other evidence of worsening heart failure 83 (11.4) 92 (13.0) 96 (13.2) 104 (14.7)
Treatment failure 47 (6.5) 43 (6.1) 42 (5.8) 37 (5.2)
Heart transplant 0 0 1 (0.1) 0
Lost to follow-up 0 0 2 (0.3) 1 (0.1)
Death or Major Cardiovascular Event
Patients with an eventc 205 (28.2) 201 (28.4) 249 (34.3) 251 (35.5)
Events (other than death or worsening heart failure)d
Myocardial infarction 15 (2.1) 11 (1.6) 19 (2.6) 15 (2.1)
Atrial fibrillation 5 (0.7) 2 (0.3) 6 (0.8) 3 (0.4)
Stroke 4 (0.6) 1 (0.1) 7 (1.0) 5 (0.7)
Myocardial ischemia 4 (0.6) 0 4 (0.6) 0
Ventricular tachycardia 3 (0.4) 1 (0.1) 4 (0.6) 1 (0.1)
Cardiac arrest 3 (0.4) 0 4 (0.6) 0
Ventricular fibrillation 2 (0.3) 4 (0.6) 3 (0.4) 5 (0.7)
aComparison between treatment groups (Fisher exact test): P = .95 at day 7 and P = .61 at day 30.
bRanked by severity; each patient counted once (as the most serious event); separate analyses for days 7 and 30, ie, a
patient in cardiogenic shock on day 6 who died on day 8 was categorized as having cardiogenic shock in the day 7
analysis and as a death in the day 30 analysis. Patients who had received a heart transplant or were lost to follow-up
were counted as treatment failure.
cComparison between treatment groups (Fisher exact test): P = .95 at day 7 and P = .66 at day 30.
dEach patient could have more than 1 event.
Table 3. Hemodynamic Changes From Baseline at 3, 6, and 24 Hours in Patients Who Underwent Pulmonary Artery Catheterization
Measure
Baseline, Mean
(95% CI)
Change From Baseline
3 h 6 h 24 h
Mean (95% CI) P Valuea Mean (95% CI) P Valuea Mean (95% CI) P Valuea
Cardiac indexb
Placebo (n = 41) 2.01 (1.86 to 2.15) 0.18 (0.00 to 0.36)
.07
0.18 (−0.02 to 0.39)
.19
0.15 (−0.08 to 0.39)
.39
Tezosentan (n = 43) 2.14 (1.98 to 2.30) 0.31 (0.17 to 0.45) 0.25 (0.11 to 0.40) 0.15 (−0.01 to 0.31)
PCWP, mm Hg
Placebo (n = 41) 25.6 (23.9 to 27.3) −1.5 (−3.0 to 0.0)
.02
−1.9 (−4.0 to 0.1)
.01
−2.9 (−5.6 to −0.1)
.24
Tezosentan (n = 43) 26.3 (24.5 to 28.1) −4.6 (−6.3 to −2.9) −5.2 (−7.1 to −3.2) −4.1 (−6.8 to −1.4)
mPAP, mm Hg
Placebo (n = 40) 35.4 (32.3 to 38.5) −0.7 (−3.1 to 1.6)
.003
−0.9 (−3.5 to 1.7)
.005
−0.8 (−4.4 to 2.7)
.07
Tezosentan (n = 42) 36.7 (34.1 to 39.3) −5.0 (−7.2 to −2.8) −5.6 (−8.1 to −3.0) −4.4 (−8.0 to −0.7)
SVR, dyne·s/cm5
Placebo (n = 41) 1813 (1590 to 2037) −157 (−361 to 47)
.02
−54 (−253 to 145)
.02
137 (−148 to 421)
.04
Tezosentan (n = 41) 1742 (1538 to 1946) −371 (−524 to −218) −306 (−475 to −137) −101 (−365 to 163)
PVR, dyne·s/cm5
Placebo (n = 40) 243 (174 to 313) 9 (−44 to 61)
.06
−21 (−32 to 75)
.03
127 (27 to 228)
.07
Tezosentan (n = 41) 232 (190 to 273) −39 (−79 to 1) −38 (−82 to 6) 53 (−36 to 142)
RAP, mm Hg
Placebo (n = 41) 15.9 (13.5 to 18.3) 0.8 (−0.6 to 2.2)
.02
−0.2 (−2.1 to 1.6)
.27
0.7 (−1.9 to 3.3)
.33
Tezosentan (n = 42) 14.6 (12.8 to 16.5) −2.0 (−3.2 to −0.7) −1.0 (−2.7 to 0.7) 0.0 (−2.4 to 2.4)
Abbrevations: CI, confidence interval; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pres-
sure; SVR, systemic vascular resistance. All values are means (standard error of mean).
aFrom Mann-Whitney U test.
bCalculated as L/min per m2.
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tients (14.5%) (P .001). At 72 hours,
the mean increase in serum urea con-
centration in the tezosentan group was
1.7 (5.0) mmol/L; in the placebo group,
it was 1.5 (6.2) mmol/L (mean differ-
ence, 0.2; 95% CI, −0.4 to 0.8; P=.58).
For the same time point, the mean in-
crease in serum creatinine concentra-
tion was 0.09 (0.35) mg/dL in the
tezosentan group and 0.07 (0.32) mg/dL
in the placebo group (mean difference,
0.02; 95% CI, −0.02 to 0.05; P=.39).
COMMENT
In VERITAS, low-dose tezosentan did
not improve dyspnea in patients stud-
ied early after an unplanned admis-
sion to hospital with acute heart fail-
ure, nor did it improve their subsequent
risk of death or nonfatal cardiovascu-
lar events. The dose of tezosentan used
in VERITAS was chosen on the basis of
a careful placebo-controlled dose-
ranging study that showed this dose to
reduce PCWP and systemic vascular re-
sistance as well as plasma concentra-
tions of BNP.13 These hemodynamic ac-
tions were confirmed in VERITAS by
the reduction in blood pressure and, in
a subset of patients, PCWP.
Why did tezosentan fail to improve
dyspnea in VERITAS, despite evidence
of improved hemodynamics? The reduc-
tion in PCWP in the small subset of
VERITAS patients with a pulmonary ar-
tery catheter was of a similar magni-
tude to that produced by tezosentan in
past studies.9,12,13 More importantly, it
was also similar to the change in PCWP
observed in trials of levosimendan and
nesiritide, in which both of those drugs
reduced dyspnea in invasively moni-
tored patients.15,16 It is possible, how-
ever, that the hemodynamic effect of the
dose of tezosentan used was less in the
nonmonitored patients in VERITAS.
Tezosentan also reduced dyspnea and
PCWP more than placebo in patients
monitored invasively in the Random-
ized Intravenous Tezosentan 2 (RITZ-2)
study (n=292). Inclusion required a low
cardiac index (2.5) and an increased
PCWP (15 mm Hg). Although a larger
dose of tezosentan (50 or 100 mg/h) was
infused in RITZ-2 than in VERITAS (1
mg/h), the effect of tezosentan on PCWP
in RITZ-2 (placebo-corrected mean re-
duction, 4.1 mm Hg) was similar to that
in the subset of patients that underwent
invasive hemodynamic monitoring in
VERITAS (placebo-corrected mean re-
duction, 3.3 mm Hg).17
One proposed explanation for the ap-
parent discrepancy between VERITAS
and these prior trials is that knowledge
of hemodynamic changes in some way
influenced the assessment of dyspnea.18
In 1 trial of nesiritide that did not re-
quire invasive hemodynamic monitor-
ing, neither dose of nesiritide improved
dyspnea more than usual therapy.16 Fur-
thermore, in the larger RITZ-1 trial, in
which patients (n=669) did not un-
dergo invasive hemodynamic monitor-
ing, treatment with tezosentan (50 mg/h)
did not improve dyspnea.19 Similarly, in
a large placebo-controlled trial of levo-
simendan that did not require hemody-
namic monitoring, there was no appar-
ent improvement in dyspnea.20 In
another trial, Vasodilation in the Man-
agement of Acute Congestive Heart Fail-
ure (VMAC), nesiritide (but not glyc-
eryl trinitrate) improved dyspnea at 3
hours, but a Food and Drug Adminis-
tration review concluded that this dif-
ference was driven by the subset of pa-
tients monitored hemodynamically.21,22
The results of 3 additional trials, how-
ever, seem to refute the hypothesis that
knowledge of hemodynamic changes
may influence the assessment of dys-
pnea, thoughcomparisonof studieswith
and without monitoring is only avail-
able for nesiritide, tezosentan, and levo-
simendan. In the Randomized Multi-
center Evaluation of Intravenous
Levosimendan Efficacy (REVIVE) trial,
levosimendan was reported to improve
dyspneacomparedwithplacebo,but fur-
ther details on the proportion of patients
monitored invasively, and the change in
dyspnea in these compared with non-
monitored patients, have not yet been
presented.23 In addition, 2 recent, large,
placebo-controlled trials showedthat the
arginine vasopressin antagonist tolvap-
tan improved patient-reported dys-
pnea, apparently without investigator
knowledge of hemodynamics.24
An alternative explanation is that the
potentially beneficial effect on breath-
lessness of reducing PCWP with
tezosentan may have been offset by an-
other, detrimental, action of endothe-
lin blockade, for example, induction of
pulmonary venous-arterial shunting
leading to desaturation.
We do not think other factors ex-
plain the difference in findings be-
tween VERITAS and the “positive” trials
of nesiritide and levosimendan. The pa-
tients in VERITAS were generally simi-
lar although somewhat older, and a
higher proportion had preserved LVEF.
However, the effect of tezosentan was
similar in all subgroups, including those
defined by age and LVEF. The sub-
group that underwent hemodynamic
monitoring in VERITAS had the same
baseline PCWP as patients in the Evalu-
ation Study of Congestive Heart Fail-
ure and Pulmonary Artery Catheter-
ization Effectiveness (ESCAPE).25
The VAS has been shown to be a
more sensitive and reproducible mea-
sure of change in dyspnea than the
Likert and Borg scales, albeit in a set-
ting other than acute heart failure.26 It
is of concern, however, that assess-
ment of the key symptom in acute heart
failure, dyspnea, has been so poorly
studied. It is also a major methodologi-
cal limitation of trials in acute heart fail-
ure that the large improvement in dys-
pnea in the placebo group (ie, in
response to usual care) makes it very
difficult to detect any additional effect
of new treatments with the most com-
monly used instruments, ie, the VAS
and Likert scales. In the recent tolvap-
tan studies, a patient-reported score for
dyspnea was used, and this did detect
a difference between active treatment
and placebo.24 Understanding whether
the efficacy differs among these differ-
ent instruments for assessing breath-
lessness will be important for the con-
duct of future trials in this area.
Tezosentan also had no effect on the
primary mortality/morbidity compos-
ite outcome (or any of the secondary
outcomes), though even with this end
point we had 80% power to detect a
25% relative risk reduction. Although
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disappointing and contrary to expec-
tations based on the potential patho-
physiological role of endothelin-1 in
heart failure, our findings are consis-
tent with earlier trials in chronic heart
failure.27-30 In those trials, long-term
treatment with oral endothelin recep-
tor antagonists had no effect on left ven-
tricular remodeling or clinical out-
comes.27-30 Conceptually, however,
short-term intravenous administra-
tion of a drug might have less pros-
pect of showing a longer-term effect on
morbidity and mortality outcomes, em-
phasizing the difficulty in evaluating
new treatment for acute heart failure.
Despite its hemodynamic actions, mil-
rinone did not reduce morbidity and
mortality in Outcomes of a Prospec-
tive Trial of Intravenous Milrinone for
Exacerbations of Chronic Heart Fail-
ure (OPTIME-CHF), and nesiritide
does not reduce morbidity or mortal-
ity in acute heart failure.31-33 Of course,
it is also possible that a beneficial effect
of tezosentan in one subgroup of pa-
tients may have been offset by harm in
another, eg, patients with a low base-
line blood pressure. VERITAS did not,
however, have the statistical power for
such an analysis, which in any case
could only be hypothesis-generating.
In summary, tezosentan, a treat-
ment with “favorable” hemodynamic
actions, failed to improve breathless-
ness or reduce fatal and nonfatal car-
diovascular events in patients follow-
ing an emergency admission to hospital
with acute heart failure. So far, it has
proved impossible to identify a thera-
peutic role for endothelin antagonists
in patients with acute or chronic heart
failure.
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